Rockpointe, the Boston University School of Medicine, and the Potomac Center for Medical Education have developed an online continuing medical education program about using Mycophenolate Risk Evaluation and Mitigation Strategy. Mycophenolic acid (MPA) is used in combination with calcineurin-inhibitor and corticosteroids to prevent rejection of transplanted organs and for various autoimmune diseases. But use of the drug during pregnancy is linked to a greater risk of pregnancy loss, congenital malformations and low birth weight. The new program, "Integrating the FDA Mycophenolate Safety Standards to Prevent Adverse Pregnancy Outcomes," is geared toward healthcare practitioners who prescribe MPAs and includes a free online activity booklet and a patient handout in multiple languages available. Participants who complete the CME course should be able to identify pregnancy and fetal risks associated with mycophenolate use in female patients of reproductive potential, provide or facilitate counseling and education to such women on the need for pregnancy prevention and planning during mycophenolate treatment, and report pregnancies that occur during mycophenolate treatment to the Mycophenolate Pregnancy Registry.

Read More